Sporadic Creutzfeldt-Jakob disease (sCJD) is the most prevalent of the human prion diseases, which are fatal and transmissible neurodegenerative diseases caused by the infectious prion protein (PrP Sc ). The origin of sCJD is unknown, although the initiating event is thought to be the stochastic misfolding of endogenous prion protein (PrP C 
). The origin of sCJD is unknown, although the initiating event is thought to be the stochastic misfolding of endogenous prion protein (PrP C ) into infectious PrP Sc . By contrast, human growth hormone-associated cases of iatrogenic CJD (iCJD) in the United Kingdom (UK) are associated with exposure to an exogenous source of PrP Sc . In both forms of CJD, heterozygosity at residue 129 for methionine (M) or valine (V) in the prion protein gene may affect disease phenotype, onset and progression. However, the relative contribution of each PrP C allotype to PrP Sc in heterozygous cases of CJD is unknown.
Using mass spectrometry, we determined that the relative abundance of PrP Sc with M or V at residue 129 in brain specimens from MV cases of sCJD was highly variable. This result is consistent with PrP C containing an M or V at residue 129 having a similar propensity to misfold into PrP Sc thus causing sCJD. By contrast, PrP Sc with V at residue 129 predominated in the majority of the UK human growth hormone associated iCJD cases, consistent with exposure to infectious PrP Sc containing V at residue 129. In both types of CJD, the PrP Sc allotype ratio had no correlation with CJD type, age at clinical onset, or disease duration. Therefore, factors other than PrP Sc allotype abundance must influence the clinical progression and phenotype of heterozygous cases of CJD.
Author Summary
In Creutzfeldt-Jakob disease (CJD), heterozygosity at residue 129 for methionine or valine in normal prion protein may affect disease phenotype, onset and progression. However, the relative contribution of each prion protein allotype to the infectious, disease associated form of prion protein (PrP Sc ) is unknown. Here we report the novel observation that in
Introduction
Prion diseases are fatal neurodegenerative disorders affecting humans and various other mammals. They are associated with the misfolding of monomeric prion protein (PrP C ) into a pathological isoform termed PrP Sc that is partially protease resistant, aggregated, and infectious.
Human prion diseases include Creutzfeldt-Jakob disease (CJD), Gerstmann-Straussler-Scheinker syndrome (GSS), kuru, fatal familial insomnia (FFI) (for review, see [1] ), PrP cerebral amyloid angiopathy [2] and variably protease-sensitive prionopathy [1, 3] . Although CJD occurs in sporadic, genetic, and iatrogenic forms, the most common form is sporadic CJD (sCJD), which occurs at approximately 1-2 cases per million people per year in any given population. Acquired forms of CJD such as kuru, variant CJD, and iatrogenic CJD (iCJD), represent a smaller percentage of all CJD cases. CJD is associated with a wide diversity of clinicopathological features [1, 4, 5] , but the factors that determine these different CJD phenotypes are still being elucidated. Sporadic CJD is classified by a neuropathological profile that appears to correlate with the biochemical properties of PrP Sc [4] [5] [6] [7] as well as the sequence of the patient prion protein gene (PRNP) at codon 129. All three genotypes of a naturally occurring amino acid polymorphism at PRNP codon 129 are found in CJD: homozygous methionine (MM) or valine (VV), and heterozygous (MV [1] . Thus, sCJD can occur with six genotype/PrP Sc type combinations: MM1, MM2, MV1, MV2, VV1, and VV2. These correspond well to the differing clinicopathological presentation found in patients in the six well-recognized sCJD phenotypic subtypes: MM1/MV1, MM2 cortical, MM2 thalamic, MV2, VV1 and VV2 [1, 8, 9] . Based on these criteria, as well as transmission studies in non-human primates [10] and transgenic mice expressing different human PRNP genotypes [11, 12] , 5 major strains of sCJD have been proposed: MM1/MV1, MV2/VV2, MM2c, MM2t and VV1 [5] . PrP Sc type
and PRNP genotype are therefore believed to be two major factors influencing CJD phenotype and pathogenesis.
Although not causing disease itself, the presence of M or V at residue 129 in PrP C does affect many aspects of prion disease susceptibility and phenotype [1, [4] [5] [6] [7] [8] [9] 13] . For example, in a familial form of human prion disease associated with an aspartic acid to asparagine mutation at residue 178 (D178N), a methionine in cis at position 129 manifests as FFI, while a valine in cis at position 129 manifests as CJD [14] . The codon 129 genotype also affects susceptibility to CJD. Methionine and valine homozygosity at codon 129 are overrepresented in sCJD patients when compared to the general population, whereas MV heterozygosity at codon 129 is underrepresented [15] [16] [17] [18] . A similar allelic distribution has been observed in human growth hormone associated cases of iCJD in France [19] . The predisposition towards homozygosity in CJD is even more pronounced in variant CJD, in which all probable and definite clinical cases reported to date have been MM homozygous [16] . By contrast, MM homozygosity is less common in human growth hormone associated cases of iCJD in the United Kingdom (UK) in which heterozygosity and VV homozygosity appear to predominate [19, 20] . Thus, the epidemiological data suggest that the effect of homozygosity or heterozygosity at codon 129 on CJD pathogenesis varies depending upon the type of CJD. There can be considerable variation within heterozygous MV1 and MV2 sCJD patients with regard to disease duration and onset [6, 9] . This variability may be due to multiple factors including the relative abundance of different populations of PrP Sc 
Results

Differentiation of M and V at residue 129 in human PrP peptides by MS
In previous MS-based analysis of purified hamster and mouse PrP Sc , we found that one of the most commonly identified PrP peptides spanned residues 111-136 (PrP111-136) [28, 29] . This peptide has also been identified by MS in PrP Sc purified from sheep scrapie [30] . In order to determine if MS analysis could also detect PrP111-136 in human PrP Sc , PK treatment followed by PTA precipitation was used to isolate PrP Sc from a sample of brain homogenate from a heterozygous case of sCJD. The same procedure was used on brain samples from several non-CJD neurological controls and the samples were compared. Only 5 PrP-specific peptides were found in one of the 3 non-CJD controls, indicating that the PrP Sc enrichment protocol used yielded little or no PrP C . By contrast, 525 total PrP peptides were found in the sCJD sample the most common of which are shown in S1 Table. Many of these peptides spanned the region of PrP from residues 111-136 and showed variable levels of methionine oxidation (S1 Table) . Importantly, the MV polymorphism at residue 129 was distinguishable based upon the unique fragmentation patterns of peptides containing either M or V (Fig 1a and 1b) . The same PrP111-136 peptides were also found, albeit with a much lower rate of methionine sulfoxidation, using rHuPrP-M129 and rHuPrP-V129 purified from E. coli (S1a and S1b Fig) . Analysis of synthetic PrP111-136 peptides containing either M or V at residue 129 confirmed that each peptide yielded distinctive spectra with precise differences between MS/MS fragments corresponding to the presence of either M or V at residue 129 (S1c and S1d Fig) . Finally, MS analysis using purified rHuPrP demonstrated that PrP111-136 peptides containing M or V at residue 129 could be differentiated with 100% specificity (S2 Fig) .
Semi-quantitative analysis of peptides containing M or V at residue 129 in human PrP
The detection of peptides with either M or V at residue 129 in PrP Sc from a heterozygous case of sCJD (Fig 1) confirmed earlier studies demonstrating the presence of both PrP Sc allotypes in two cases of heterozygous sCJD [24, 25] . Therefore, both PrP Sc -M129 and PrP Sc -V129 might contribute to sCJD pathogenesis. However, the relative abundance and thus potential extent of the contribution of each allotype to disease pathogenesis is unknown. Spectral counting, which is defined as the number of MS spectra identified for a protein, is a semi-quantitative technique that is often used as a practical method for estimating protein abundance [31] . It provides a robust label-free estimate for comparing the relative abundance of proteins in or between sample groups [32] . We first determined the quantitative relationship between PrP concentration and spectral counts using MS analysis of a solution of purified rHuPrP stoichiometrically adjusted to contain different molar ratios of rHuPrP-M129 and V129 (S2 Fig). There was a good correlation between spectral counts and the concentration of rHuPrP-M129 (R 2 = 0.89).
At a molar ratio of 50:50, 56 ± 2% of the PrP111-136 peptides were identified as M129 while approximately 44 ± 2% contained V129. Thus, spectral counting allowed us to estimate the relative abundance of M or V at residue 129 in a heterozygous mixture of human PrP, albeit with a slight bias towards detection of the M versus the V PrP111-136 peptide. Therefore, we used a spectral counting approach to semi-quantitatively determine the relative amounts of PrP Sc -
M129 and PrP
Sc -V129 in brain tissue derived from heterozygous cases of sCJD.
Variable abundance of M and V at residue 129 in PrP Sc isolated from sCJD brain Patient brain samples from 14 cases of heterozygous sCJD were analyzed and their clinical and molecular data are presented in Table 1 . The prominent neuropathological features of each case are described in S2 Table and exemplified by images of PrP immunohistochemistry performed on cerebral cortex (CC) and, where relevant to this study, cerebellar cortex (CbC) samples (Fig 2a) . No PrP Sc is detected in non-CJD brain using this technique (for an example see S3a Fig) . The pathological and molecular features correspond broadly to the histopathological types proposed by Parchi et al [5] . However, in certain cases, such as case 3, there was a discrepancy between molecular and histopathological findings (see S2 Table) suggesting an atypical case of MV1 sCJD. Age of onset for the sCJD cases analyzed ranged from 53-77 years (mean ± SD = 64.7 ± 7.3) while disease duration ranged from 4-21 months (mean ± SD = 10.9 ± 5.7). Molecular analysis had previously identified 5 of the cases as being of the MV1 sCJD subtype (cases 1-5) and 9 as being of the MV2 sCJD subtype (cases 6-14) ( samples from one sCJD MV1 case specimen consistently showed a mobility slightly ahead of the Type 1 reference standard (Fig 3a, case 4 ). The blots further resolved the presence of a Type 2 doublet (2d) in 6 out of the 9 MV2 subtype cases (Table 1 and Fig 3a) . The relative amounts of the two doublets varied between samples from equivalence (case 10 CC) to barely detectable amounts of the least abundant band (case 7 CC). None of the sCJD specimens examined contained both Type 1 and 2 PrP Sc (Fig 3a) . No PrP Sc is detectable in PK-treated non-CJD brain using this technique (for an example see S3b Fig) . PrP Sc enriched from the cerebral cortex or cerebellar cortex of the 14 cases of heterozygous sCJD as well as 3 non-CJD neurological controls was analyzed by MS. For each patient sample, the number of PrP spectra spanning residues PrP111-136 was determined. Using the data analysis criteria described in the materials and methods, an average of >5 PrP111-136 spectra were identified in every sCJD sample examined but not in the non-CJD controls. (Fig 3b) . We next determined if the relative abundance of PrP Sc -M129 and PrP Sc -V129 could also vary between brain regions within an individual sCJD patient. The relative abundance of PrP Sc -M129 and PrP Sc -V129 in the CbC was compared to that of the CC in one MV1 and three MV2 sCJD cases (Table 1 ). There were no major differences in the amount of PrP Sc - M129 (Fig 4) or the type of PrP Sc deposition (Fig 2a) in the cerebral and cerebellar samples from cases 3 and 7. However, the amount of PrP Sc -M129 (Fig 4) as well as the type of PrP Sc deposition (Fig 2a) differed significantly between brain regions in the two other cases, 9 and 14. While only 4 sCJD cases were analyzed, the data suggest that within the same patient the Sc -M129 (black bars) detected in the CC or CbC (samples 3, 7, 9, and 14 only) of sCJD patients. Each bar represents n = 3-4 technical replicates except for case 4 where n = 2. A stoichiometrically adjusted solution of 50% rHuPrP-M129 and 50% rHuPrP-V129 (rPrP (50%), hatched bar) was used as a control (n = 8). Statistical analysis was done using a 1-way ANOVA with Dunnett's post-test using rPrP (50%) as the control sample. * p = 0.01 to 0.05, **p = 0.001 to 0.01, ***p = 0.0001 to 0.01, ****p <0.000. represented only 34% of the total PrP Sc identified (Table 1) . Thus, despite significant differences between cases, the MV ratio of the PrP Sc allotypes did not appear to overtly influence disease onset or progression. There was evidence that PrP Sc allotype might influence disease phenotype in some heterozygous sCJD patients. In two cases, 9 and 14, differences in the PrP Sc allotype ratio between brain regions (Fig 4) were associated with different neuropathologies (Fig 2a) . However, when all of the MV sCJD cases were compared, there was no definitive correlation between the amount of PrP Sc -M129 and various neuropathological features such as the presence of amyloid plaques, pattern of PrP Sc deposition or type of spongiform change (S2 Table) .
Relative abundance of M and V at residue 129 in PrP Sc isolated from iCJD brain
Next we determined the relative abundance of PrP Sc -M129 in brain samples from 6 cases of iCJD, all of whom were heterozygous at codon 129 in PRNP (see Table 2 for clinical and molecular data). The prominent neuropathological features of each case are described in S2 Table  and exemplified by images of PrP immunohistochemistry performed on cerebral cortex samples in Fig 2b. The mean age of onset for the iCJD cases was younger than that of the sCJD cases, ranging from 27-33 years (mean ± SD of 30.3 ± 2.4) while disease duration was longer than that of the sCJD cases, ranging from 8-32 months (mean ± SD of 17.8 ± 8.5). Western blot analysis of a tissue sample from the specimen used for MS using the method of Parchi et al. [33] showed that Type 2 PrP Sc predominated in all six cases. In 4 of the 6 samples, this took the form of a Type 2 doublet (2d) and in the other two it was found to be a mixture of Type 2 and a smaller amount of Type 1 (2+1) ( Table 2 and Fig 5a) . As with the heterozygous cases of sCJD, there was no significant correlation between the amount of PrP Sc -M129 and disease duration or age of onset (p > 0.3, Table 2 ). However, as shown in Fig 5b, 4 Epidemiological, genetic and neuropathological data all suggest that human growth hormone associated cases of iCJD in the UK may be the result of contamination with the MV2 or VV2 subtype of sCJD [19, 20] . We therefore compared the PrP Sc allotype ratio to the major neuropathological phenotypes represented in both the sCJD and iCJD cases. As with disease onset and duration, there was no correlation between sCJD PrP Sc allotype and Type 1 and Type 2 sCJD cases with similar neuropathological phenotypes (Fig 6) . Both the sCJD MV1 + 2C and MV2K + 2C cases segregated into three distinct groups based on PrP Sc allotype ratio with no significant difference in the mean percentage of PrP Sc -M129 between the two types (Fig 6a and   6b ). Interestingly, sCJD MV2K and iCJD MV2K had a somewhat similar PrP Sc allotype distribution with no statistically significant difference in the mean percentage of PrP Sc -M129 (Fig 6c   and 6d) . With the caveat that only 2 cases of sCJD MV2K were available for analysis, these data are nonetheless consistent with the hypothesis that UK cases of human growth hormone associated iCJD are the result of exposure to the V2 strain of human prion.
Discussion
Efficient conversion of PrP C to PrP Sc can be strongly dependent upon homology at a single amino acid residue in PrP C [35] , including residue 129 [36, 37] , and differences in key amino acid residues can effect disease onset and progression [27, 38, 39] . However, we found no [23] or increased protease-sensitivity [21] , may have a more significant influence on age of onset or duration of clinical disease than the presence of an M or V at residue 129 in Type 1 or Type 2 PrP Sc .
The epidemiological associations of Type 1 PrP Sc with methionine homozygosity and Type 2 PrP Sc with valine homozygosity within sCJD patient cohorts could be used to argue that the presence of methionine at position 129 of the prion protein predisposes it to misfold to a Type 1 conformation, whereas the presence of valine at the same position predisposes it to misfold to a Type 2 conformation. If this were so, then one might predict that Type 1 PrP Sc in heterozygous sCJD cases would be largely composed of PrP Sc -M129 whereas Type 2 PrP Sc in heterozygous sCJD cases would be largely composed of PrP Sc -V129 [37] . Data from transmission studies in transgenic mice [11, 12, 41] and in vitro assays of PrP Sc formation [37] are consistent with this prediction. It was therefore surprising that in our study we saw no correlation between PrP Sc type and PrP Sc allotype (Fig 3b) . Out of the 5 MV1 sCJD cases analyzed, PrP Sc -M129 was the dominant allotype in only one case while PrP Sc -V129 was the most prevalent allotype in 3 of the 9 MV2 cases analyzed (Fig 3b) . It is therefore unlikely that the amino acid (Fig 6a and 6b) . These data are based primarily on the relative abundance of PrP Sc -M129
and PrP Sc -V129 in the cerebral cortex. It is possible, however, that there may be some correlation with phenotypic differences between brain regions in the same patient. In cases 9 and 14, where distinctive pathologies were observed in the cerebral cortex and cerebellar cortex (Fig 2) , the PrP Sc allotype ratios were also significantly different (Fig 4) . By contrast, in two cases where neuropathology was similar between these two brain regions (cases 3 and 7, Figs 2 and 4 was the most abundant allotype, or both allotypes were equally represented (Fig 3b) . The relatively equal representation of the different possible PrP Sc allotypes does not appear to be consistent with one PrP C molecule being more predisposed to misfold into PrP Sc than the other, as has been suggested by several in vitro studies [42] [43] [44] In contrast with sCJD, the heterozygous cases of iCJD analyzed were more homogeneous, with a higher proportion of PrP Sc -V129 in most of the cases (Fig 5b) . As with the sCJD cases, aetiology may provide an explanation for the greater PrP Sc allotype homogeneity of the iCJD samples. In cases of iCJD prior to 2003 which were linked to human growth hormone therapy in the UK, 96% had the VV or MV PRNP genotype at codon 129 [19] . In patients diagnosed after 2008, this percentage had decreased to 86% [20] . Based on the earlier cases, Brandel et al. [19] first proposed that the UK cases were caused by either sCJD VV2 or sCJD MV2, a conclusion supported by the more recent study [20] . Our data showing that 1) PrP Sc -V129 is the dominant PrP Sc allotype in the majority of the UK human growth hormone-associated iCJD cases analyzed and 2) that the PrP Sc allotype distribution between sCJD MV2K and these cases (Fig 6c and 6d) is very similar, are also entirely consistent with this conclusion. It is thus possible that the PrP Sc -M129 to PrP Sc -V129 ratio in heterozygous iCJD patient cohorts might be a means of determining the prion strain that initiated infection. Unlike sCJD, iCJD is a secondary infection of CJD in humans. Selective pressures in the original host with sCJD as well as in the secondary host with iCJD may influence the final PrP Sc allotype ratio. If PrP Sc -V129 in the infectious material was of the VV2 type, when transmitted to a second host it would likely interact most efficiently with PrP C -V129 to form PrP Sc . As a result, PrP Sc -V129
would more than likely be the predominant PrP Sc allotype in the infected iCJD patient. Used in this way, mass spectrometry analysis of heterozygous PrP Sc could be the molecular equivalent of in vivo traceback studies that have used the transmission properties of iCJD into transgenic mice [47, 48] or non-human primates [10] to determine the prion strain originally responsible for infection in groups of patients.
Materials and Methods
Reagents and supplies
Trypsin was purchased from Promega. Burdick & Jackson water and acetonitrile (ACN) were purchased from VWR. Imperial Coomassie blue stain and iodoacetamide were purchased from Thermo-Fisher Scientific. Formic acid (FA), dithiothreitol (DTT), trifluoroethanol (TFE), phosphotungstic acid (PTA), benzonase, and protein extraction reagent (7M urea, 2M thiourea, 1% C 7 BzO, 40 mM Tris, pH 10.4) were purchased from Sigma-Aldrich.
Ethics statement
Human brain samples were obtained from the National CJD Research & Surveillance Unit Brain and Tissue Bank in Edinburgh, UK, which is part of Edinburgh Brain Banks. For the purposes of this study, samples were pseudoanonymized using a Brain Bank reference number. Cerebellar and cerebral cortex tissue from two additional sCJD patients were obtained from the University of Verona, Italy. These tissues were obtained at autopsy and sent to the Neuropathology Unit at the University of Verona for statutory definite diagnosis of CJD. All UK cases had consent for research and their supply and use in this study was covered by LREC 2000/4/157 (National Creutzfeldt-Jakob disease tissue bank: acquisition and use of autopsy material for research on human transmissible spongiform encephalopathies, Professor James Ironside, amended date: 9 th October 2007). Ethical approval for the acquisition and use of human brain material was obtained from the National Institutes of Health (NIH) Office of Human Subject Research (Exempt #11763 and #12725) and no patient identifiable data was transferred to the NIH.
Recombinant prion protein (rPrP)
Human recombinant prion proteins spanning residues 23-231 and containing either methionine or valine at residue 129 (rHuPrP-M129 and rHuPrP-V129, respectively) were cloned into a pET41a vector using NdeI-XhoI restriction enzymes. The proteins were expressed as inclusion bodies using Escherichia coli Rosetta cells and then purified as described for recombinant hamster PrP [49] . Briefly, guanidine denatured PrP from bacterial inclusion bodies was clarified by centrifugation, bound to NiNTA resin (Qiagen), and then subjected to on-column refolding without reducing agents using a non-denaturing refolding buffer (10mM Tris, 100mM sodium phosphate, pH 8). After elution using refolding buffer adjusted to pH 5.8 and 500mM imidazole, PrP was immediately sterile-filtered, dialyzed into 10mM ammonium formate pH 4.5, and stored at -80°C at a concentration of~0.3mg/mL until needed. Consistent with our previous results [49] , all PrP preparations were approximately 99% pure. In addition, the molecular weight of purified recombinant PrP was verified by intact mass analysis using a Sciex 4000 QTrap system.
PrP peptides
Synthetic PrP111-136 peptides containing either M or V at residue 129 were diluted in water with 3% ACN/0.1% formic acid and used without further modification after having been subjected to HPLC and MALDI in order to establish purity and the correct molecular weight.
Allotype ratio concentration curve
Concentrations of purified rHuPrP-M129 and rHuPrP-V129 proteins were determined individually by absorbance at 280nm and then adjusted to contain molar ratios of 0:100, 25:75, 50:50, 75:25, or 100:0 rHuPrP-M129 to rHuPrP-V129, respectively. Final mixtures containing 0.3mg/mL total rPrP were mixed 1:1 with 2X sample buffer (Life Technologies), boiled for 5 min and subjected to SDS-PAGE. Coomassie blue staining displayed a single strong band which was excised and subjected to in-gel trypsin digestion as described below. At least 8 lanes (n = 8-9) were used per individual rPrP mixture and each was subjected to mass spectrometry analysis as described below.
Human brain tissue
Approximately 2g samples of cerebral cortex (CC) and (in some cases) cerebellar cortex (CbC) from sCJD, iCJD and non-CJD neurological controls were analysed. All cerebral cortex samples were of grey matter enriched frontal cortex with the exception of cases 3 and 14 which were from the occipital cortex. Additionally, grey matter enriched cerebellar cortex samples were analyzes from cases 3, 7, 9 and 14. The choice of frontal cortex reflects both its involvement in MV1 sCJD, MV2 sCJD, and UK human growth hormone-related MV iCJD as well as tissue availability. The selection of cerebellum as a second region to analyze was based on it providing a contrast to the cerebral cortex as well as the known pronounced involvement of the cerebellum in MV2 sCJD. The diagnosis of definite sCJD or definite iCJD had previously been reached using internationally recognised criteria (http://www.cjd.ed.ac.uk/documents/criteria.pdf) and the cases had been characterised in terms of their neuropathology, PRNP codon 129 genotype, and predominant PrP Sc type. The 20 CJD cases examined comprised 14 cases of sCJD in heterozygous patients (5 of the MV1 and 9 of the MV2 molecular subtypes) and 6 cases of iatrogenic CJD in heterozygous patients (all of which were of the MV2 molecular subtype). The three non-CJD neurological cases analyzed were initially suspected of having CJD, but post mortem examination resulted in an alternative diagnosis. These three patients were a 78 year old male with a pathological diagnosis of Lewy body dementia, a 66 year old female with a pathological diagnosis of arteriosclerosis and a seventy year old female with a pathological diagnosis of arteriosclerosis. Western blot analysis had previously failed to detect PrP Sc in the brain in these cases and the PRNP codon 129 genotypes of the three patients were VV, MV and MM respectively.
Neuropathological review
A detailed neuropathological review of the sCJD and iCJD cases analysed in this study was conducted and cases were sub-classified with reference to the sCJD histotypes reported by Parchi et al [5] .
Western blot analysis and typing of PrP Sc
To confirm the presence of PrP Sc and to provide a definitive type for the PrP Sc present in the brain specimen being used for mass spectrometry, a 100mg tissue sample was removed from each brain specimen and analysed by western blotting. The stringent sample preparation and proteinase K digestion conditions of Parchi et al 2009 were used [33] that allow distinction to be made between Type 1 (1), Type 2 (2), a mixture of Type 2 and Type 1 (2+1) and doublets of Type 2 (2d).
Enrichment of PrP Sc using phosphotungstic acid
Brain tissue samples for mass spectrometry were homogenized in phosphate buffered saline (PBS, pH 7.4) to a final concentration of 20% (w/v) using a Mini-BeadBeater-8 (Biospec) and stored in aliquots at -80°C until needed. Enrichment of PrP Sc was performed using PTA precipitation as described previously [50] with some modifications [51] . Briefly, 250 μL of a 20% brain homogenate was diluted to 10% with PBS and then mixed with 500μL of 4% sarkosyl/ PBS. Following incubation at 37°C for 30 min, samples were treated with benzonase at 50U/ mL for 1 hour and then clarified by a 5 min centrifugation at 5,000 g. The supernatants were then digested with PK (50 μg/mL) for 1 hour at 37°C. PTA was added to a final concentration of 0.3% (w/v) and the sample incubated at 37°C for 2 hours. Samples were centrifuged for 30 min at 16,100 x g, the pellets suspended in 200μL of PBS with 200mM EDTA, incubated at 37°C for 30 min, and centrifuged as before. The pellets were resuspended in 200μL PBS, incubated at 37°C for 30 min, and the sample again collected by centrifugation. The final pellet was used for analysis of PrP Sc by mass spectrometry as detailed below.
Reduction, alkylation and tryptic digestion of PrP Sc
Samples of PrP Sc pelleted by PTA precipitation were solubilized in 25μL of protein extraction reagent (7M urea, 2M thiourea, 1% C 7 BzO) and DTT added to a final concentration of 14mM. Following a 30 min incubation at 37°C, iodoacetamide was added to a final concentration of 75mM and the sample incubated in the dark at room temperature for 30 min. The reaction was quenched by the addition of 1M DTT to a final concentration of 200mM followed by the addition of 12μL of 4X NuPAGE sample buffer (Life Technologies). Denatured, reduced and alkylated samples of enriched PrP Sc were briefly heated to 100°C using a heating block prior to loading onto a 10% Bis-Tris 1.5mm gel for SDS-PAGE. Gels were stained with Coomassie blue (Imperial stain, Thermo-Fisher Scientific) but the bands corresponding to PrP Sc were often too faint to be detected by eye. Therefore, the area of the gel lane encompassing molecular mass markers from~10kDa to 80kDa, including the area of the gel containing PrP Sc , was divided into 8 gel slices. In-gel trypsin digestion was then performed as described previously [28] . 
Data analysis
Raw data were processed into MGF peak lists using MASCOT Distiller v2.4.3.0. The MGF files were searched using MASCOT Daemon against a target database (www.uniprot.org) filtered for human taxonomy consisting of 20,235 entries which included an entry for PrP111-136 containing V at residue 129 in addition to the default Swiss-Prot entry containing the full PrP sequence with M at residue 129. The trypsin/P search parameters for MASCOT protein identification consisted of one missed tryptic cleavage allowed with a fixed carbamidomethylation (+57, Cys) and a variable oxidation (+16, Met). Mass tolerances of 2.0 and 1.0 Daltons were used for parent and monoisotopic fragment ions, respectively. The resulting DAT files generated by MASCOT were used as input files for spectral counting using the ProteoIQ bioinformatics platform (Premier Biosoft Inc) [52] with the constraints that only MASCOT ion scores of 30 and only peptides of 7 amino acids in length were considered in these calculations. The number of PrP spectra from each sample were then compared to the other samples that had been processed using the same protocols and the same instrument parameters. In PTA precipitates from the 3 non-CJD brains examined, only 5 PrP peptides were detected in a single sample following a total of 72 MS runs. This indicated that little or no PrP C was present in the final non-CJD PTA pellet. A background threshold of 5 total PrP peptides was therefore used to exclude any potential contribution of PrP C to the final PTA pellet and all 3 non-CJD samples were considered negative for PrP Sc . By contrast, all PTA precipitated sCJD and iCJD samples had total PrP spectral counts at least 26-fold above the background threshold of 5 spectral counts. Only western blot positive samples yielding greater than 5 PrP111-136 peptides were utilized for semi-quantitation as spectral counts of less than 5 spectra are considered to be unreliable for spectral counting [32, 53] .
Statistics
Mean and standard deviation (SD) were derived using the individual technical replicates described above. Supporting Information 
